CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. Show more
Location: 835 Industrial Road, San Carlos, CA, 94070, United States | Website: https://cargo-tx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
216.7M
52 Wk Range
$3.00 - $25.45
Previous Close
$4.48
Open
$4.47
Volume
1,808,728
Day Range
$4.45 - $4.49
Enterprise Value
-35.32M
Cash
252.6M
Avg Qtr Burn
-47.4M
Insider Ownership
0.63%
Institutional Own.
97.78%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|